Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
  • G01N33/6818—Sequencing of polypeptides
  • G01N33/6824—Sequencing of polypeptides involving N-terminal degradation, e.g. Edman degradation
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
  • G01N33/6818—Sequencing of polypeptides
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
  • G01N2440/12—Post-translational modifications [PTMs] in chemical analysis of biological material alkylation, e.g. methylation, (iso-)prenylation, farnesylation
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
  • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
  • G01N2440/18—Post-translational modifications [PTMs] in chemical analysis of biological material citrullination
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
  • G01N2440/26—Post-translational modifications [PTMs] in chemical analysis of biological material nitrosylation

Definitions

• Post-translational modifications (PTMs) of proteins are covalent attachments of chemical moieties on the side chains of select amino acids or the N and C terminus of a peptide or a protein.
• the activity and functions of many proteins are modulated by the nature of their PTMs.
• Some non-limiting examples of PTMs include phosphorylation, glycosylation, alkylation, acylation, hydroxylation, or the attachment of a cofactor or nucleotide.
• PTMs include phosphorylation, glycosylation, alkylation, acylation, hydroxylation, or the attachment of a cofactor or nucleotide.
• One such example is the C-terminal domain of the Epidermal growth factor receptor (EGFR) family of proteins that contains approximately 20 tyrosine residues capable of being phosphorylated.
• EGFR Epidermal growth factor receptor
• the downstream processes can range from cell proliferation, differentiation, anti-apoptosis (survival), adhesion, migration, and angiogenesis (Huang et al. , 2011). Understanding and mapping these sites is thus critical not only to better understand cell signaling pathways, but also develop the current therapeutic drugs.
• mapping post- translational modifications have been intrinsically challenging due to their low abundance and sample heterogeneity.
• the current methods do not allow for precise determination of the specific location of PTMs while also allowing for quantitative determination of the PTMs. Therefore, there remains an unmet need to identify methods which allow from improved detection of PTMs in a protein or peptide.
• the present disclosure provides methods and systems for protein or peptide sequencing and/or protein or peptide identification. Methods and systems of the present disclosure may be used to sequence a protein or peptide for the determination of a post- translational modification(s) and the location(s) of such post-translational modification(s).
• the present disclosure provides methods of identifying a post translational modification on an amino acid residue of a peptide or protein, the method comprising:
• the post translational modification on the amino acid residue is phosphorylation, glycosylation, nitrosylation, citrullination, sulfenylation, or trimethylation.
• the post translational modification on the amino acid residue is phosphorylation on tyrosine, serine, or threonine.
• the post translational modification on the amino acid residue is phosphorylation on a serine.
• the post translational modification on the amino acid residue is phosphorylation on a threonine.
• the post translational modification on the amino acid residue is an /V-glycosylation.
• the post translational modification on the amino acid residue is glycosylation of asparagine or arginine. In other embodiments, the post translational modification on the amino acid residue is an O- glycosylation. In some embodiments, the post translational modification on the amino acid residue is glycosylation of serine, threonine, or tyrosine. In other embodiments, the post translational modification on the amino acid residue is trimethylation. In some embodiments, the post translational modification on the amino acid residue is trimethylation of lysine. In other embodiments, the post translation modification on the amino acid residue is nitrosylation. In some embodiments, the post translation modification on the amino acid residue is nitrosylation of a cysteine or tyrosine.
• the post translation modification on the amino acid residue is nitrosylation of a cysteine. In other embodiments, the post translation modification on the amino acid residue is nitrosylation of a tyrosine. In other embodiments, the post translation modification on the amino acid residue is citrullination. In other embodiments, the post translation modification on the amino acid residue is sulfenylation. In some embodiments, the post translational modification on the amino acid residue is sulfenylation of a cysteine.
• the post translation modification is on an amino acid residue of a protein. In other embodiments, the post translation modification is on an amino acid residue of a peptide.
• the labeling reagent comprises a thiol group. In some embodiments, the labeling reagent comprises two thiol groups. In some embodiments, the labeling reagent comprises an amine reactive group such as a succinimidyl ester. In some embodiments, the labeling reagent comprises a glyoxal group. In some embodiments, the labeling reagent comprises a l,3-cycloalkanedione group such as a 1,3- hexanedione.
• the labeling reagent is a fluorophore, oligonucleotide, or peptide-nucleic acid.
• the labeling reagent is a fluorophore.
• the labeling reagent is a thiol containing fluorophore.
• the fluorophore is a xanthene dye such as a rhodamine dye.
• the methods involve treating the peptide or protein with the labeling reagent comprises:
• the reactive peptide or protein is formed by treating the peptide or protein comprising a phosphorylation post translational modification with a base.
• the base is a rare earth metal hydroxide such as Ba(OH)2.
• the reactive peptide or protein is formed by treating the peptide or protein comprising a phosphorylation post translational modification with an activating agent and a base.
• the activating agent is a carbodiimide such as l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC).
• the base is a heteroaromatic base such as an imidazole.
• the reactive peptide or protein is formed by treating the peptide or protein comprising a trimethyl post translational modification with silver oxide (Ag20). In some embodiments, the peptide or protein comprising a trimethyl post translational modification is treated with silver oxide in the presence of heat. In some embodiments, the reactive peptide or protein is formed by treating the peptide or protein comprising a trimethyl post translational modification with a base. In some embodiments, the base is a nitrogenous base such as diisopropylethylamine or trimethylamine.
• the reactive peptide or protein is formed by treating the peptide or protein comprising a glycosylation post translational modification with an oxidizing agent.
• the oxidizing agent is a hypervalent iodide reagent such as sodium periodate.
• the reactive peptide or protein is formed by treating the peptide or protein comprising a nitrosylation post translational modification with a reducing agent.
• the reducing agent is disulfide reducing agent such as dithiothreitol.
• the reducing agent further comprises heme.
• the reactive peptide or protein is formed by treating the peptide or protein comprising a nitrosylation post translational modification with phosphine.
• the phosphine is an unsubstituted or substituted trialkylphosphine or an unsubstituted or substituted a triarylphosphine.
• the phosphine is an unsubstituted or substituted triarylphosphine. In some embodiments, the phosphine is an unsubstituted or substituted triphenylphosphine. In some embodiments, the methods involve contacting the peptide or protein with the labeling reagent comprises reacting the peptide or protein comprising a post translational modification with a phosphine. In some embodiments, the phosphine is an unsubstituted or substituted trialkylphosphine or an unsubstituted or substituted triarylphosphine. In some embodiments, the phosphine is an unsubstituted or substituted triarylphosphine. In some embodiments, the phosphine is an unsubstituted or substituted triphenylphosphine. In some embodiments, the phosphine is covalently linked to the labeling reagent.
• the methods involve contacting the peptide or protein with the labeling reagent comprises reacting the peptide or protein comprising a post translational modification with a glyoxal group.
• the glyoxal group is covalently linked to the labeling reagent.
• the methods involve contacting the peptide or protein with the labeling reagent comprises reacting the peptide or protein comprising a post translational modification with a l,3-cycloalkanedione such as a l,3-cyclohexanedione.
• the l,3-cycloalkanedione is covalently bonded to the labeling reagent.
• the reactive group on the reactive peptide or protein is a double bond.
• the reactive peptide or protein is treated with the labeling reagent comprising a thiolene-click reaction to form a labeled peptide or protein.
• the reactive peptide or protein is treated with the labeling reagent with a double bond in the presence of an olefin metathesis reagent to form a labeled peptide or protein.
• the reactive peptide or protein is treated with the labeling reagent comprising a cycloaddition reaction to form a labeled peptide or protein.
• the reactive group on the reactive peptide or protein is an aldehyde.
• the labeling reagent is treated with the reactive group on the reactive peptide or protein comprising nucleophilic addition, nucleophilic substitution, or radical addition.
• the labeling reagent forms a thioether when treated with the reactive group on the reactive peptide or protein.
• the labeling reagent forms a dithiane.
• the reactive peptide or protein is treated with the labeling reagent to form an amide bond. In some embodiments, the amide bond formation provides the labeled peptide or protein.
• the reactive peptide or protein is treated with the labeling reagent to form a disulfide bond. In some embodiments, the disulfide bond formation provides the labeled peptide of protein. In some embodiments, the reactive peptide or protein is treated with the labeling reagent to form a heterocycloalkane. In some embodiments, the heterocycloalkyl group formation provides the labeled peptide of protein. In some embodiments, the reactive peptide or protein is treated with the labeling reagent to form a thioether bond. In some embodiments, the thioether bond formation provides the labeled peptide of protein. [0018] In some embodiments, the sequencing comprises a fluorosequencing method.
• the sequencing is at a single molecular level.
• the fluorosequencing method comprises labeling at least one amino acid of the peptide or protein which does not contain a post translational modification with a second labeling reagent.
• the fluorosequencing method comprises labeling one, two, three, four, or five distinct amino acids of the peptide or protein which do not contain a post translation modification.
• each amino acid is labeled with a distinct second labeling reagent.
• the peptide or protein is bound to a solid support such as a surface.
• the solid support is a resin, a bead, or a modified glass surface.
• the solid support is the modified glass surface such as an aminosilicate surface.
• the fluorosequencing method further comprises removing at least one amino acid residue of the peptide or protein. In some embodiments, the fluorosequencing method comprises sequentially removing two or more consecutive amino acid residues of the peptide or protein. In some embodiments, the fluorosequencing method comprises sequentially removing amino acid residues of the peptide or protein until a labeled amino acid comprising a modified post translational modification is removed. In some embodiments, the fluorosequencing method comprises sequentially removing from 1 to 20 amino acid residues of the peptide or protein until a labeled amino acid comprising a modified post translational modification is removed. In some embodiments, the amino acid residues are removed by Edman degradation. In some embodiments, the amino acid residue is removed by treating the /V- terminal amino acid residue with a thiourea and an acid, microwave irradiation, or heat. In some embodiments, the amino acid residues are removed by an enzyme.
• the peptide or protein is digested by a protease. In some embodiments, the peptide or protein is digested by a protease before labeling the amino acid comprising the post translational modification. In some embodiments, the peptide or protein is obtained from a biological sample. In some embodiments, the biological sample is a cell-free biological sample. In some embodiments, the biological sample is derived from blood. In other embodiments, the biological sample is derived from urine. In other embodiments, the biological sample is derived from mucous. In other embodiments, the biological sample is derived from saliva.
• a covalent bond between the post translational modification on the amino acid residue of the peptide or protein and the labeling reagent is formed.
• the labeling reagent or derivative thereof is directly covalently bonded to the amino acid residue.
• the labeling reagent or derivative thereof is covalently coupled to the amino acid residue through an intermediary molecule.
• the present disclosure provides methods of determining the status of a disease or disorder in a subject, the method comprising:
• the methods further comprise obtaining a biological sample from the subject.
• determining the status of a disease or disorder is determining the prognosis of the patient that has the disease.
• determining the status of a disease or disorder is diagnosing the patient with the disease.
• determining the status of a disease or disorder is determining if the patient is at risk of having the disease.
• the change in post translation modification of a protein or peptide is a change in the phosphorylation of the protein. In other embodiments, the change in post translation modification of a protein or peptide is a change in the trimethylation of the protein. In other embodiments, the change in post translation modification of a protein or peptide is a change in the glycosylation of the protein. In other embodiments, the change in post translation modification of a protein or peptide is a change in the nitrosylation of the protein. In some embodiments, the change in post translation modification of a protein or peptide is a change in the citrullination of the protein. In some embodiments, the change in post translation modification of a protein or peptide is a change in the sulfenylation of the protein.
• the biological sample is a cell-free biological sample such as saliva, mucous, urine, serum, plasma, or whole blood.
• the method conveys the presence of one or more post translational modifications. In some embodiments, the method conveys the presence of two or more post translation modifications. In some embodiments, the method conveys the absence of one or more post translational modifications. In some embodiments, the method conveys the absence of one or more post translational modifications and the presence of one or more post translational modifications.
• the method conveys the type of the post translational modification in the protein. In some embodiments, the method conveys the identity of the post translational modification in the protein. In some embodiments, the method conveys the quantity of the post translational modification in the protein. In some embodiments, the method conveys the position of the post translational modification in the protein. In some embodiments, the subject is a mammal such as a human.
• the method further comprises enriching the protein before determining the type, identity, quantity, or position of the post translational modifications.
• the protein is enriched by purification of the biological sample.
• the protein is subjected to degradation before determining the types or identities of the post translational modifications.
• the protein is degraded by a protease.
• the protein is immobilized on a solid support.
• the solid support is a surface.
• the solid support is a resin, a bead, or a modified glass surface.
• the solid support is the modified glass surface such as an aminosilicate surface.
• the method comprises determining the type, identity, quantity, or position of post translational modification on two or more peptides or proteins.
• the present disclosure provides methods for determining the status of a disease or disorder in a subject, the method comprising: detecting a change in a type, identity, quantity, or position of the post translational modifications on the protein or peptide using the methods described herein related to the disease or disorder.
• the methods further comprise obtaining a biological sample from the subject.
• the present disclosure provides modified peptides or proteins comprising a peptide or protein comprising one or more post translational modifications, wherein at least one post translational modification of said peptide or protein comprising one or more post translational modifications is altered with at least a first labeling moiety, thereby forming a labeled peptide or protein comprising one or more post translational modifications.
• the at least the first labeling moiety is a fluorophore.
• the peptide or protein comprises a second labeling moiety attached to one or more amino acid residues of the peptide or protein.
• the second labeling moiety is a fluorophore.
• said at least one post translational modification is selected from the group consisting of phosphorylation, glycosylation, nitrosylation, citrullination, sulfenylation, trimethylation, or any combination thereof.
• each post translational modification selected from the group consisting of phosphorylation, glycosylation, nitrosylation, citrullination, sulfenylation, or trimethylation is altered by a distinct labeling moiety.
• the modified peptide or protein comprises from 3 amino acid residues to about 250 amino acid residues. In some embodiments, the modified peptide or protein comprises from 5 amino acid residues to about 100 amino acid residues. In some embodiments, the modified peptide or protein comprises from about 7 amino acid residues to about 50 amino acid residues.
• the first labeling reagent replaces the post translational modification on the amino acid residue.
• the post translation modification is on an amino acid residue of a protein.
• the post translation modification is on an amino acid residue of a peptide.
• the first labeling reagent comprises a thiol group.
• the first labeling reagent comprises two thiol groups.
• the first labeling reagent comprises an amine reactive group such as a succinimidyl ester.
• the first labeling reagent comprises a glyoxal group.
• the first labeling reagent comprises a l,3-cycloalkanedione group such as a l,3-hexanedione.
• the first or second labeling reagent are a fluorophore, oligonucleotide, or peptide-nucleic acid.
• the one of the first or second labeling reagent is a fluorophore.
• the labeling reagent is a thiol containing fluorophore.
• the fluorophore is a xanthene dye such as a rhodamine dye.
• the second labeling moiety is attached to a different type of amino acid of the peptide or protein than the first labeling moiety.
• the methods further comprise one or more additional labeling moieties attached to one or more distinct amino acids of the peptide or protein.
• the peptide or protein is immobilized adjacent to a solid support.
• the solid support is a surface.
• the solid support is a resin, a bead, or a modified glass surface.
• the solid support is a modified glass surface such as an aminosilicate surface.
• the peptide or protein has been degraded by a protease.
• the post translation modification is phosphorylation of the peptide or protein.
• the post translation modification is trimethylation of the peptide or protein.
• the post translation modification is glycosylation of the peptide or protein.
• the post translation modification is nitrosylation of the peptide or protein.
• the post translation modification is citrullination of the peptide or protein.
• the post translation modification is sulfenylation of the peptide or protein.
• the post translational modification on the amino acid residue is phosphorylation on tyrosine, serine, or threonine. In some embodiments, the post translational modification on the amino acid residue is phosphorylation on a serine. In other embodiments, the post translational modification on the amino acid residue is phosphorylation on a threonine. In other embodiments, the post translational modification on the amino acid residue is an /V-glycosylation. In some embodiments, the post translational modification on the amino acid residue is glycosylation of asparagine or arginine. In other embodiments, the post translational modification on the amino acid residue is an O- glycosylation.
• the post translational modification on the amino acid residue is glycosylation of serine, threonine, or tyrosine. In other embodiments, the post translational modification on the amino acid residue is trimethylation. In some embodiments, the post translational modification on the amino acid residue is trimethylation of lysine. In other embodiments, the post translation modification on the amino acid residue is nitrosylation. In some embodiments, the post translation modification on the amino acid residue is nitrosylation of a cysteine or tyrosine. In some embodiments, the post translation modification on the amino acid residue is nitrosylation of a cysteine. In other embodiments, the post translation modification on the amino acid residue is nitrosylation of a tyrosine.
• the post translation modification on the amino acid residue is citrullination. In other embodiments, the post translation modification on the amino acid residue is sulfenylation. In some embodiments, the post translational modification on the amino acid residue is sulfenylation of a cysteine.
• the present disclosure provides methods of sequencing a peptide or protein comprising:
• the post translational modification on the amino acid residue is phosphorylation, glycosylation, nitrosylation, citrullination, sulfenylation, or trimethylation.
• the post translational modification on the amino acid residue is phosphorylation on tyrosine, serine, or threonine.
• the post translational modification on the amino acid residue is phosphorylation on a serine.
• the post translational modification on the amino acid residue is phosphorylation on a threonine.
• the post translational modification on the amino acid residue is an /V-glycosylation.
• the post translational modification on the amino acid residue is glycosylation of asparagine or arginine. In other embodiments, the post translational modification on the amino acid residue is an O- glycosylation. In some embodiments, the post translational modification on the amino acid residue is glycosylation of serine, threonine, or tyrosine. In other embodiments, the post translational modification on the amino acid residue is trimethylation. In some embodiments, the post translational modification on the amino acid residue is trimethylation of lysine. In other embodiments, the post translation modification on the amino acid residue is nitrosylation. In some embodiments, the post translation modification on the amino acid residue is nitrosylation of a cysteine or tyrosine.
• the post translation modification on the amino acid residue is nitrosylation of a cysteine. In other embodiments, the post translation modification on the amino acid residue is nitrosylation of a tyrosine. In other embodiments, the post translation modification on the amino acid residue is citrullination. In other embodiments, the post translation modification on the amino acid residue is sulfenylation. In some embodiments, the post translational modification on the amino acid residue is sulfenylation of a cysteine.
• the labeling reagent replaces the post translational modification on the amino acid residue.
• the post translation modification is on an amino acid residue of a protein.
• the post translation modification is on an amino acid residue of a peptide.
• the labeling reagent comprises a thiol group.
• the labeling reagent comprises two thiol groups.
• the labeling reagent comprises an amine reactive group such as a succinimidyl ester.
• the labeling reagent comprises a glyoxal group.
• the labeling reagent comprises a 1,3- cycloalkanedione group such as a l,3-hexanedione.
• the labeling reagent is a fluorophore, oligonucleotide, or peptide-nucleic acid. In some embodiments, the labeling reagent is a fluorophore. In some embodiments, the labeling reagent is a thiol containing fluorophore. In some embodiments, the fluorophore is a xanthene dye such as a rhodamine dye.
• the reactive peptide or protein is formed by treating the peptide or protein comprising a phosphorylation post translational modification with a base.
• the base is a rare earth metal hydroxide such as Ba(OH)2.
• the reactive peptide or protein is formed by treating the peptide or protein comprising a phosphorylation post translational modification with an activating agent and a base.
• the activating agent is a carbodiimide such as l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC).
• the base is a heteroaromatic base such as an imidazole.
• the reactive peptide or protein is formed by treating the peptide or protein comprising a trimethyl post translational modification with silver oxide (Ag20). In some embodiments, the peptide or protein comprising a trimethyl post translational modification is treated with silver oxide in the presence of heat. In some embodiments, the reactive peptide or protein is formed by treating the peptide or protein comprising a trimethyl post translational modification with a base. In some embodiments, the base is a nitrogenous base such as diisopropylethylamine or trimethylamine.
• the reactive peptide or protein is formed by treating the peptide or protein comprising a glycosylation post translational modification with an oxidizing agent.
• the oxidizing agent is a hypervalent iodide reagent such as sodium periodate.
• the reactive peptide or protein is formed by treating the peptide or protein comprising a nitrosylation post translational modification with a reducing agent.
• the reducing agent is disulfide reducing agent such as dithiothreitol.
• the reducing agent further comprises heme.
• the reactive peptide or protein is formed by treating the peptide or protein comprising a nitrosylation post translational modification with phosphine.
• the phosphine is an unsubstituted or substituted trialkylphosphine or an unsubstituted or substituted a triarylphosphine.
• the phosphine is an unsubstituted or substituted triarylphosphine. In some embodiments, the phosphine is an unsubstituted or substituted triphenylphosphine. In some embodiments, the methods involve contacting the peptide or protein with the labeling reagent comprises reacting the peptide or protein comprising a post translational modification with a phosphine. In some embodiments, the phosphine is an unsubstituted or substituted trialkylphosphine or an unsubstituted or substituted triarylphosphine. In some embodiments, the phosphine is an unsubstituted or substituted triarylphosphine. In some embodiments, the phosphine is an unsubstituted or substituted triphenylphosphine. In some embodiments, the phosphine is covalently linked to the labeling reagent.
• the methods involve contacting the peptide or protein with the labeling reagent comprises reacting the peptide or protein comprising a post translational modification with a glyoxal group.
• the glyoxal group is covalently linked to the labeling reagent.
• the methods involve contacting the peptide or protein with the labeling reagent comprises reacting the peptide or protein comprising a post translational modification with a l,3-cycloalkanedione such as a l,3-cyclohexanedione.
• the l,3-cycloalkanedione is covalently bonded to the labeling reagent.
• the reactive group on the reactive peptide or protein is a double bond.
• the reactive peptide or protein is treated with the labeling reagent comprising a thiolene-click reaction to form a labeled peptide or protein.
• the reactive peptide or protein is treated with the labeling reagent with a double bond in the presence of an olefin metathesis reagent to form a labeled peptide or protein.
• the reactive peptide or protein is treated with the labeling reagent comprising a cycloaddition reaction to form a labeled peptide or protein.
• the reactive group on the reactive peptide or protein is an aldehyde.
• the labeling reagent is treated with the reactive group on the reactive peptide or protein comprising nucleophilic addition, nucleophilic substitution, or radical addition.
• the labeling reagent forms a thioether when treated with the reactive group on the reactive peptide or protein.
• the labeling reagent forms a dithiane.
• the reactive peptide or protein is treated with the labeling reagent to form an amide bond. In some embodiments, the amide bond formation provides the labeled peptide or protein.
• the reactive peptide or protein is treated with the labeling reagent to form a disulfide bond. In some embodiments, the disulfide bond formation provides the labeled peptide of protein. In some embodiments, the reactive peptide or protein is treated with the labeling reagent to form a heterocycloalkane. In some embodiments, the heterocycloalkyl group formation provides the labeled peptide of protein. In some embodiments, the reactive peptide or protein is treated with the labeling reagent to form a thioether bond. In some embodiments, the thioether bond formation provides the labeled peptide of protein.
• the sequencing comprises a fluorosequencing method. In some embodiments, the sequencing is at a single molecular level. In some embodiments, the fluorosequencing method comprises labeling at least one amino acid of the peptide or protein which does not contain a post translational modification with a second labeling reagent. In some embodiments, the fluorosequencing method comprises labeling one, two, three, four, or five distinct amino acids of the peptide or protein which do not contain a post translation modification. In some embodiments, each amino acid is labeled with a distinct second labeling reagent.
• the peptide or protein is bound to a solid support such as a surface.
• the solid support is a resin, a bead, or a modified glass surface.
• the solid support is the modified glass surface such as an aminosilicate surface.
• the fluorosequencing method further comprises removing at least one amino acid residue of the peptide or protein. In some embodiments, the fluorosequencing method comprises sequentially removing two or more consecutive amino acid residues of the peptide or protein. In some embodiments, the fluorosequencing method comprises sequentially removing amino acid residues of the peptide or protein until a labeled amino acid comprising a modified post translational modification is removed. In some embodiments, the fluorosequencing method comprises sequentially removing from 1 to 20 amino acid residues of the peptide or protein until a labeled amino acid comprising a modified post translational modification is removed. In some embodiments, the amino acid residues are removed by Edman degradation.
• the amino acid residue is removed by treating the /V- terminal amino acid residue with a thiourea and an acid, microwave irradiation, or heat. In some embodiments, the amino acid residues are removed by an enzyme. [0056] In some embodiments, the peptide or protein is digested by a protease. In some embodiments, the peptide or protein is digested by a protease before labeling the amino acid comprising the post translational modification.
• the present disclosure provides methods for polypeptide sequence identification, comprising:
• said first polypeptide is a protein.
• the present disclosure provides methods for processing or analyzing a protein or peptide containing or suspected of containing at least one post-translational modification, comprising: (A) sequencing said protein or peptide, and
• said sequencing comprises subjecting said protein or peptide to degradation conditions to sequentially remove amino acid sub-units from said protein or peptide, and detecting at least a subset of said amino acid sub-units. In some embodiments, less than all amino acid sub-units of said peptide or protein are labeled, and wherein said sequencing comprises detecting a subset of said amino acid sub-units.
• said at least one post-translational modification is identified during said sequencing. In some embodiments, said at least one post-translational modification is identified prior to said sequencing.
• said protein or peptide is obtained from a sample and processed to label said at least one post-translational modification.
• said sample is a cell-free sample.
• said sequencing comprises labeling said at least one post-translational modification of said protein or peptide with a label, and detecting said label to thereby identify said at least one post- translational modification on said protein or peptide.
• the present disclosure provides methods for processing or analyzing a protein or peptide, comprising subjecting said protein or peptide to conditions sufficient to specifically label different post-translational modifications of said protein or peptide, and detecting labels corresponding to said different post-translational modifications of said protein or peptide to thereby detect said different post-translational modifications of said protein or peptide.
• said different post-translational modifications comprise phosphorylation, glycosylation, nitrosylation, citrullination, sulfenylation, or trimethylation.
• “essentially free,” in terms of a specified component may refer to a specified component being absent from a composition or the component is present as a contaminant or in trace amounts. The total amount of the specified component resulting from any unintended contamination of a composition can be below 0.1%. In some embodiments, a composition in which no amount of the specified component can be detected with standard analytical methods.
• “a” or“an” may refer to one or more.
• the words“a” or“an” when used in conjunction with the word“comprising”, the words“a” or“an” may refer to one or more than one.
• “another” or“a further” may refer to at least a second or more.
• the term“about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects. In some embodiments, the term“about” refers to ⁇ 5% of the listed value.
• FIG. 1 Correct identification of phosphoserine residues on synthetic CTD heptad peptide by fluorosequencing.
• (Top) Phosphoserine is present at the 2 nd position.
• (Bottom) Phosphoserine is present at the 5 th position.
• Representative raw imaging data are shown for two individual peptide molecules from each experiment. For each individual molecule, the images are organized as a horizontal strip of consecutive TIRF micrographs (each corresponding to a square of 3 x 3 microns) centered on the peptide molecule. Each image represents one successive observation of emitted fluorescent light from that molecule after a round of Edman chemistry.
• a sharp reduction in fluorescence follows the Edman cycle in which the ammo acid with the attached fluorescent dye was removed, thus revealing the amino acid sequence position of the phosphorylated residue m the original peptide.
• the heatmap denotes the frequency histogram, tallying the counts of individual peptide molecules having lost fluorescence after every Edman degradation cycle over the background counts.
• the phosphorylated serine residue in the 2 nd position (top) and 5 th position (bottom) have significantly higher counts of fluorescent loss at the 2 nd and 5 th position, respectively, when analyzed by the fluorosequencing method.
• FIG. 2 shows fluorosequencing position counts between two biological samples. Proteins from two different HEK-293T samples were digested, labeled, and sequenced on the fluorosequencing platform. Read counts were observed to be highly correlated between these biological replicates (Pearson coefficient 0.9582). Data is counts and plotted on a loglO scale DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
• the present disclosure provides methods of typing, identifying, quantifying, or locating a post translational modification (PTM) in a peptide or protein. These methods may be used to determine the type, location, quantity, or position of a PTM such as phosphorylation, glycosylation, or alkylation in a peptide or protein. These methods may be used in conjunction with a fluorosequencing method such as those which include labeling of the post translational modification with a labeling moiety such as a fluorophore. These methods may further include the removal of one or more amino acid residues from the peptide or protein. In some aspects, these methods may be used to determine the progression or status of a disease or disorder in a patient.
• PTM post translational modification
• Fluorosequencing has been found to provide single molecule resolution for the sequencing of proteins of interest (Swaminathan, 2010; U.S. Patent No. 9,625,469; U.S. Patent Application Serial No. 15/461,034; U.S. Patent Application Serial No. 15/510,962).
• fluorosequencing is introduction of a fluorophore or other label into specific amino acid residues of the peptide sequence. This can involve the introduction of one or more amino acid residues with a unique labeling moiety.
• one, two, three, four, five, or more different amino acids residues are labeled with a labeling moiety.
• the labeling moiety that may be used include fluorophores, chromophores, or a quencher.
• Each of these amino acid residues may include cysteine, lysine, glutamic acid, aspartic acid, tryptophan, tyrosine, serine, threonine, arginine, histidine, methionine, asparagine, and glutamine.
• Each of these amino acid residues may be labeled with a different labeling moiety.
• multiple amino acid residues may be labeled with the same labeling moiety such as aspartic acid and glutamic acid or asparagine and glutamine. While this technique may be used with labeling moieties such as those described above, it is also contemplated that other labeling moiety may be used in fluorosequencing-like methods such as synthetic oligonucleotides or peptide-nucleic acid may be used. In particular, the labeling moiety used in the instant applications may be suitable to withstand the conditions of removing one or more of the amino acid residues.
• labeling moieties that may be used in the instant methods include those which emit a fluorescence signal in the red to infrared spectra such as an Alexa Fluor® dye, an Atto dye, a rhodamine dye, or other similar dyes. Examples of each of these dyes which were capable of withstanding the conditions of removing the amino acid residues include Alexa Fluor® 405, Rhodamine B, tetramethyl rhodamine, Alexa Fluor 555, Atto647N, and (5)6-napthofluorescein. In other aspects, it is contemplated that the labeling moiety may be a fluorescent peptide or protein or a quantum dot.
• oligonucleotides or oligonucleotide derivatives may be used as the labeling moiety for the peptides.
• thiolated oligonucleotides may be coupled to peptides using the presented methods.
• Commonly available thiol modifications are 5' thiol modifications, 3' thiol modifications, and dithiol modifications and each of these modifications may be used to modify the peptide.
• the peptides may be subjected to Edman degradation (Edman el al, 1950) and the oligonucleotides may be used to determine the presence of a specific amino acid residue in the remaining peptide sequence.
• the labeling moiety may be a peptide-nucleic acid.
• the peptide-nucleic acid may be attached to the peptide sequence on specific amino acid residues.
• One element of fluorosequencing is the removal of the labeled peptides through such techniques such as Edman degradation and subsequent visualization to detect a reduction in fluorescence, indicating a specific amino acid has been cleaved. Removal of each amino acid residue is carried out through a variety of different techniques including Edman degradation and proteolytic cleavage.
• the techniques include using Edman degradation to remove the terminal amino acid residue.
• the techniques involve using an enzyme to remove the terminal amino acid residue. These terminal amino acid residues may be removed from either the C terminus or the N terminus of the peptide chain. In situations in which Edman degradation is used, the amino acid residue at the N terminus of the peptide chain is removed.
• the methods of sequencing or imaging the peptide sequence may comprise immobilizing the peptide on a surface.
• the peptide may be immobilized using an cysteine residue, the N terminus, or the C terminus.
• the peptide is immobilized by reacting the cysteine residue with the surface.
• the present disclosure contemplates immobilizing the peptides on a surface such as a surface that is optically transparent across the visible spectra, the infrared spectra, or a combination thereof possesses a refractive index between 1.3 and 1.6, is between 10 to 50 nm thick, is chemically resistant to organic solvents as well as strong acid such as trifluoroacetic acid, or any combination thereof.
• a large range of substrates like fluoropolymers (Teflon-AF (Dupont), Cytop® (Asahi Glass, Japan)), aromatic polymers (polyxylenes (Parylene, Kisco, Calif.), polystyrene, polymethmethylacrytate) and metal surfaces (Gold coating)), coating schemes (spin-coating, dip-coating, electron beam deposition for metals, thermal vapor deposition and plasma enhanced chemical vapor deposition) and functionalization methodologies (polyallylamine grafting, use of ammonia gas in PECVD, doping of long chain end-functionalized fluorous alkanes etc) may be used in the methods described herein as a useful surface.
• a 20 nm thick, optically transparent fluoropolymer surface made of Cytop® may be used in the methods described herein.
• the surfaces used herein may be further derivatized with a variety of fluoroalkanes that will sequester peptides for sequencing and modified targets for selection.
• an aminosilane modified surfaces may be used in the methods described herein.
• the methods described herein may comprise immobilizing the peptides on the surface of beads, resins, gels, quartz particles, glass beads, or combinations thereof.
• the methods contemplate using peptides that have been immobilized on the surface of Tentagel® beads, Tentagel® resins, or other similar beads or resins.
• the surface used herein may be coated with a polymer, such as polyethylene glycol.
• the surface is amine functionalized.
• the surface is thiol functionalized.
• Each of these sequencing techniques involves imaging the peptide sequence to determine the presence of one or more labeling moiety on the peptide sequence. In some embodiments, these images are taken after each removal of an amino acid residue and used to determine the location of the specific amino acid in the peptide sequence. In some embodiments, the methods can result in the elucidation of the location of the specific amino acid in the peptide sequence. These methods may be used to determine the locations of specific amino acid residues in the peptide sequence or these results may be used to determine the entire list of amino acid residues in the peptide sequence. The methods may involve determining the location of one or more amino acid residues in the peptide sequence and comparing these locations to specific peptide sequences and determining the entire list of amino acid residues in the peptide sequence.
• the methods may comprise labeling one or more additional amino acid residues which do not contain a post translational modification.
• These amino acids may be labeled with a labeling moiety which is different from the label used to label the amino acid residue containing the post translational modification. If more than one position on the peptide is labeled, it is contemplated that the amino acids are labeled in the following order: cysteine, lysine, N terminus, C terminus, amino acids with carboxylic acid groups on the side chain, tryptophan, or any combination thereof. It is contemplated that one or more of these particular amino acids may be labeled or all of these amino acid residues may be labeled with different labels.
• the imaging methods used in the sequencing techniques may involve a variety of different methods such as fluorimetry and fluorescence microscopy.
• the fluorescent methods may employ such fluorescent techniques such as fluorescence polarization, Forster resonance energy transfer (FRET), or time-resolved fluorescence.
• fluorescence microscopy may be used to determine the presence of one or more fluorophores in the single molecule quantity.
• imaging methods may be used to determine the presence or absence of a label on a specific peptide sequence. After repeated cycles of removing an amino acid residue and imaging the peptide sequence, the position of the labeled amino acid residue can be determined in the peptide.
• the present methods comprise labeling and determining the presence and position, location, quantity, type of a post translational modification of a peptide sequence, or any combination thereof.
• Post translational modifications are used to refer to a covalent modification of a protein or peptide through enzymatic or non-enzymatic modification of the protein or peptide.
• the post translational modification includes both natural as well as non-natural modifications.
• Post translational modifications may be used to describe a variety of different types of covalent modifications including a modification to the side chain of an amino acid or cleaving of peptide (or amide) bonds, or as a result of oxidative stress. Often post translational modifications are attached to the side chain of an amino acid.
• side chains of amino acids which contain a nucleophilic side chain are often the site of a post translational modification.
• the side chains of amino acids, which may be modified include nucleophilic sites such as the hydroxyl groups of amino acids serine, threonine, and tyrosine, the amine group of amino acids lysine, arginine, and histidine, the thiol group of cysteine, and the carboxylic acid group of aspartate and glutamine.
• post translational modifications include addition of a hydrophobic group such as alkylation which may be used to introduce one or more alkyl such as methyl groups, acylation which may be used to introduce one or more acyl group such as acetylation, formylation, or acylation with a fatty acid, or prenylation which introduces a isoprenoid group.
• Other post translational modifications may include the introduction of a cofactor or translation factors such as a flavin moiety, a heme moiety, lipoylation, or diphthamide formation.
• Other post translation modification may comprise the introduction of another protein such as SUMOylation, which attaches a SUMO protein, or ubiquitination, which attaches the protein ubiquitin.
• Post translational modifications may further comprise the introduction of a chemical group to an existing amino acid residue.
• chemical groups which can be used to modify an amino acid residue include acylation, alkylation, amide bond formulation, carboxylation, glycosylation, hydroxylation, iodination, phosphorylation, nitrosylation, sulfmylation, sulfenylation, sulfation, or succinylation.
• the present methods may be used to determine the presence of one or more of these post translational modifications.
• the post translational modification is an alkylation specifically a methylation to introduce a mono, di or trimethylamine group to the side chain of the lysine residue.
• the post translational modification is the phosphorylation of a hydroxyl group on tyrosine, threonine, or serine residue especially a threonine or a serine residue.
• the post translational modification is a glycosylation of a nitrogen or oxygen atom in the side chain of an amino acid.
• the peptides or proteins with a post translational modification described herein may be obtained from a biological sample.
• These biological samples may be obtained from an animal or plant source.
• One potential animal source is a mammal source such as a sample obtained from a human.
• the human source may be obtained from a baby, an adolescent, or an adult human.
• These biological samples may include cell-free samples.
• a cell-free sample may be a sample which is free of cells, substantially free of cells or essentially free of cells.
• a cell-free biological sample may include a protein(s), peptide(s), amino acid(s), a nucleic acid molecule(s) (e.g., ribonucleic acid molecule or deoxyribonucleic acid molecule), or any combination thereof. While a sample may be denoted as cell-free, the sample may contain a small number of cells or cell debris while still being considered cell- free.
• these samples may include less than or equal to about 50 cells or fewer per milliliter of sample, 45 cells per milliliter, 40 cells per milliliter, 35 cells per milliliter, 30 cells per milliliter, 25 cells per milliliter, 20 cells per milliliter, 15 cells per milliliter, 10 cells per milliliter, 5 cells per milliliter, 1 cell per milliliter, or less.
• these samples may include greater than or equal to about 1 cell per milliliter, 5 cells per milliliter, 10 cells per milliliter, 15 cells per milliliter, 20 cells per milliliter, 25 cells per milliliter, 30 cells per milliliter, 35 cells per milliliter, 40 cells per milliliter, 45 cells per milliliter, 45 cells per milliliter, 50 cells per milliliter, or more.
• Such cell-free samples may include blood (e.g., whole blood), serum, plasma, saliva, urine, or mucous, for example.
• amino acid in general refers to organic compounds that contain at least one amino group,— NFh which may be present in its ionized form,— NH 3 + , and one carboxyl group,— COOH, which may be present in its ionized form,— COO .
• carboxylic acids are deprotonated at neutral pH, having the basic formula of NH2CHRCOOH.
• An amino acid and thus a peptide has an N (amino)-terminal residue region and a C (carboxy)-terminal residue region.
• Types of amino acids include at least 20 that are considered“natural” as they comprise the majority of biological proteins in mammals and include amino acid such as lysine, cysteine, tyrosine, threonine, etc.
• Amino acids may also be grouped based upon their side chains such as those with a carboxylic acid groups (at neutral pH), including aspartic acid or aspartate (Asp; D) and glutamic acid or glutamate (Glu; E); and basic amino acids (at neutral pH), including lysine (Lys; L), arginine (Arg; N), and histidine (His; H).
• terminal is referred to as singular terminus and plural termini.
• side chains refers to unique structures attached to the alpha carbon (attaching the amine and carboxylic acid groups of the amino acid) that render uniqueness to each type of amino acid.
• R groups have a variety of shapes, sizes, charges, and reactivities, such as charged polar side chains, either positively or negatively charged, such as lysine (+), arginine (+), histidine (+), aspartate (-) and glutamate (-), amino acids can also be basic, such as lysine, or acidic, such as glutamic acid; uncharged polar side chains have hydroxyl, amide, or thiol groups, such as cysteine having a chemically reactive side chain, i.e.
• Non-polar hydrophobic amino acid side chains include the amino acid glycine; alanine, valine, leucine, and isoleucine having aliphatic hydrocarbon side chains ranging in size from a methyl group for alanine to isomeric butyl groups for leucine and isoleucine; methionine (Met) has a thiol ether side chain, proline (Pro) has a cyclic pyrrolidine side group.
• Phenylalanine (with its phenyl moiety) (Phe) and typtophan (Trp) (with its indole group) contain aromatic side groups, which are characterized by bulk as well as nonpolarity.
• Amino acids can also be referred to by a name or 3-letter code or 1 -letter code, for example, Cysteine; Cys; C, Lysine; Lys; K, Tryptophan; Trp; W, respectively.
• Amino acids may be classified as nutritionally essential or nonessential, with the caveat that nonessential vs. essential may vary from organism to organism or vary during different developmental stages. Nonessential or conditional amino acids for a particular organism is one that is synthesized adequately in the body, typically in a pathway using enzymes encoded by several genes, as substrates allow for protein synthesis.
• Essential amino acids are amino acids that the organism is not unable to produce or not able to produce enough naturally, via de novo pathways, for example lysine in humans. Humans obtain essential amino acids through their diet, including synthetic supplements, meat, plants and other organisms.
• “Unnatural” amino acids are those not naturally encoded or found in the genetic code nor produced via de novo pathways in mammals and plants. They can be synthesized by adding side chains not normally found or rarely found on amino acids in nature.
• b amino acids which have their amino group bonded to the b carbon rather than the a carbon as in the 20 standard biological amino acids, are unnatural amino acids.
• a common naturally occurring b amino acid is b-alanine.
• the term the terms“amino acid sequence”,“peptide”,“peptide sequence”,“polypeptide”, and“polypeptide sequence” are used interchangeably herein to refer to at least two amino acids or amino acid analogs that are covalently linked by a peptide (amide) bond or an analog of a peptide bond.
• the term peptide includes oligomers and polymers of amino acids or amino acid analogs.
• the term peptide also includes molecules that are commonly referred to as peptides, which generally contain from about two (2) to about twenty (20) amino acids.
• the term peptide also includes molecules that are commonly referred to as polypeptides, which generally contain from about twenty (20) to about fifty amino acids (50).
• peptide also includes molecules that are commonly referred to as proteins, which generally contain from about fifty (50) to about three thousand (3000) amino acids.
• the amino acids of the peptide may be /.-amino acids or //-amino acids.
• a peptide, polypeptide or protein may be synthetic, recombinant or naturally occurring.
• a synthetic peptide is a peptide that is produced by artificially in vitro.
• the term“subset” refers to the A-terminal amino acid residue of an individual peptide molecule.
• A“subset” of individual peptide molecules with an N- terminal lysine residue is distinguished from a“subset” of individual peptide molecules with an A-terminal residue that is not lysine.
• the term“substituted” may refer to a compound in which one or more hydrogen atoms on the parent molecule has been replaced with another group such that the group does not substantially alter the essential function for which the compound. More specifically, the term“substituted” means that the referenced group may be substituted with one or more additional group(s) individually and independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, -OH, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, -CN, alkyne, Ci-C6alkylalkyne, halo, acyl, acyloxy, -CO2H, -C02-alkyl, nitro, haloalkyl, fluoroalkyl, and amino, including mono- and di-substituted
• the protecting groups that may form the protective derivatives of the above substituents are found in sources such as Greene and Wuts, above.
• a non-limiting list of possible chemical groups includes -OH, -F, -Cl, -Br, -I, -NH 2 , -NO2, -CO2H, -CO2CH3, -CO2CH2CH3, -CN, -SH, -OCH3, -OCH2CH3, -C(0)CH 3 , -NHCH3, -NHCH2CH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , -C(0)N(CH 3 ) 2 , -OC(0)CH 3 , -NHC(0)CH 3 , -S(0) 2 OH, or -S(0) 2 NH 2 .
• fluorescence refers to the emission of visible light by a substance that has absorbed light of a different wavelength.
• fluorescence provides a non-destructive way of tracking, analyzing, or a combination of tracking and analyzing biological molecules based on the fluorescent emission at a specific wavelength.
• Proteins including antibodies
• peptides including nucleic acid, oligonucleotides (including single stranded and double stranded primers) may be“labeled” with a variety of extrinsic fluorescent molecules referred to as fluorophores.
• sequencing of peptides“at the single molecule level” refers to amino acid sequence information obtained from individual (i.e. single) peptide molecules in a mixture of diverse peptide molecules.
• the present disclosure may not be limited to methods where the amino acid sequence information obtained from an individual peptide molecule is the complete or contiguous amino acid sequence of an individual peptide molecule. In some embodiment, it is sufficient that partial amino acid sequence information is obtained, allowing for identification of the peptide or protein. Partial amino acid sequence information, including for example the pattern of a specific amino acid residue (i.e. lysine) within individual peptide molecules, may be sufficient to uniquely identify an individual peptide molecule.
• a pattern of amino acids such as X-X-X-Lys-X-X-X-X-Lys-X-Lys, which indicates the distribution of lysine molecules within an individual peptide molecule, may be searched against a specific proteome of a given organism to identify the individual peptide molecule. It is not intended that sequencing of peptides at the single molecule level be limited to identifying the pattern of lysine residues in an individual peptide molecule; sequence information for any amino acid residue (including multiple amino acid residues) may be used to identify individual peptide molecules in a mixture of diverse peptide molecules.
• single molecule resolution refers to the ability to acquire data (including, for example, amino acid sequence information) from individual peptide molecules in a mixture of diverse peptide molecules.
• the mixture of diverse peptide molecules may be immobilized on a solid surface (including, for example, a glass slide, or a glass slide whose surface has been chemically modified).
• this may include the ability to simultaneously record the fluorescent intensity of multiple individual (i.e. single) peptide molecules distributed across the glass surface.
• optical devices that can be applied in this manner. For example, a conventional microscope equipped with total internal reflection illumination and an intensified charge- couple device (CCD) detector is available (see Braslaysky el al, 2003).
• Imaging with a high sensitivity CCD camera allows the instrument to simultaneously record the fluorescent intensity of multiple individual (i.e. single) peptide molecules distributed across a surface.
• image collection may be performed using an image splitter that directs light through two band pass filters (one suitable for each fluorescent molecule) to be recorded as two side-by-side images on the CCD surface.
• Using a motorized microscope stage with automated focus control to image multiple stage positions in the flow cell may allow millions of individual single peptides (or more) to be sequenced in one experiment.
• Attribution probability mass function for a given fluorosequence, the posterior probability mass function of its source proteins, i.e. the set of probabilities P(pi/fi) of each source protein pi, given an observed fluorosequence fi.
• the peptide was precipitated with cold ether and centrifuged for 10 mins at 8000 ref.
• the pellet was resuspended in acetonitrile/water (1 : 1 v:v mixture) and purified by high-performance liquid chromatography (Shimadzu Inc.) with an Agilent® Zorbax® column (4.6 c 250 mm) operating at 10 mL/min flow rate with a gradient of 5-95% methanol (0.1% formic acid) over 90 minutes.
• the fraction containing the peptide was collected, and the volume reduced using a rotary evaporator before lyophilization.
• Atto647N-SH Single dye-thiol reagent Atto647N-SH was prepared by reacting the Atto647N-S-S-Atto647N reagent with 1 mM tris(2-carboxyethyl)phosphine (TCEP) and incubating it for 1 h at 60 °C.
• TCEP tris(2-carboxyethyl)phosphine
• the TCEP addition to break the disulfide linkage in the dye-thiol reagent can be performed prior to the addition of the dye-thiol reagent to the mixture.
• the entire contents of the reaction was then diluted to 2 mL with acetonitrile/water mixture (1 : 1 v:v), and HPLC separated (as above).
• the fluorescent fractions monitored at 640 nm absorbance by the diode-array detector on HPLC, were then collected, as they correspond to the phosphorylated peptide.
• labeled phosphorylated peptide was lyophilized.
• the phosphate group present on any modified amino acids can be labeled by the EDC/Imidazole reaction mechanism (shown in Scheme 1).
• the reaction has been described for oligonucleotides and can also be used for labeling pyrophosphates on amino acids as well and has been adapted from Wang el al. , 1993.
• the phosphorylated peptide is reacted with 0.1 M imidazole, 0.1 M EDC and 0.25 M of donor amine (fluorophore) in pH 7.5 buffer such as PBS buffer (e.g., ⁇ 10 mM).
• the reaction is kept at 50 °C for 20 minutes.
• the labeled peptide is subsequently purified and sequenced by single molecule sequencing method.
• Scheme 1 Pan Modification of Phosphorylated Amino Acid Residues
• HEK-293T Human Embryonic kidney 293 transgenic (HEK-293T) cells were cultured and lysed using a modified RIPA buffer. Proteins were quantified and isolated from the cell lysate prior to labeling. Proteins were then denatured, and digested with the protease trypsin at a 1:50 ratio of trypsin enzyme to protein. Following digestion, a 10 kDa filter was used to filter out peptides. All phosphorylated serines and threonines in solution were then labeled using the following techniques. Phosphorylated residues were converted to the beta-eliminated variants using Ba(OH)2. A Michael addition reaction was then used to couple the fluorophore Atto 647N with a thiol modification to the beta-eliminated resides. Fluorescently labeled peptides were then purified and lyophilized.
• Fluorosequencing allows for low abundance variations of protein/peptide molecules to be identified and is described in Swaminathan, 2010; U.S. Patent No. 9,625,469; U.S. Patent Application Serial No. 15/461034; U.S. Patent Application Serial No. 15/150,962.
• This method relies on specific labeling of amino acids with fluorophores to determine its position in the peptide chain. This method can be similarly extended to identify the positions of modified amino acids by use of sugar specific fluorophores.
• the concept for labeling glyocosylated amino acids is a two-step process.
• the first step oxidizes the alcohol groups of sugar moieties to aldehydes.
• the second step then reacts the dithiol reagent with the aldehyde group of the sugar molecule. It has been shown that l,3-dithiane does not degrade when exposed to sequencing conditions, thus the inventors identified ways to modify fluorophores to have a 1, 3-dithiol tether to label glycosylated amino acids.
• Atto647N-SH Single dye-thiol reagent Atto647N-SH was prepared by reacting the Atto647N-S-S-Atto647N reagent with 1 mM tris(2-carboxyethyl)phosphine (TCEP) and incubating it for 1 h at 60 °C.
• TCEP tris(2-carboxyethyl)phosphine
• Fluorosequencing has been shown to precisely map the positions of fluorescently labeled amino acid residues on peptides at a sensitivity of a single molecule, and may be useful for the identification of lysine trimethylation as described in Swaminathan, 2010; U.S. Patent No. 9,625,469; U.S. Patent Application Serial No. 15/461034; U.S. Patent
• Nitric oxide is a cell-signaling molecule that is synthesized by a family of enzymes known as nitric oxide synthetases. NO can react with metalloproteins or covalently modify tyrosine and cysteine residues through oxidation or production of reactive nitrogen species. Nitrosylation is this category of post-translational modification that produce a covalent addition of L'-nitrosylation on cysteines or nitration on tyrosine residues (See Scheme 7). Detecting and quantifying the modification have implications for better understanding of the signaling processes during stress or inflammation and developing diagnostics (Abello et al, 2009).
• Protein/peptide isolation Proteins are harvested from the cells using protocols common in molecular biology (Lee, 2017) and digested into peptides by common proteases, such as trypsin or GluC. In some scenarios it is feasible to fix cells by treating it with cold methanol (-20 °C) or other methods of cell fixation. Following fixation, the cells may be directly reacted with the reagent to label surface accessible PTM.
• Blocking free thiols In order to carry out the L'-nitrosylation labeling reaction, the free thiols present on cysteine should be blocked. Two common reagents used in the procedure are iodoacetamide and A-methy 1 mal ei mi de. 2-20 mM of the reagent is used at pH 7.5 buffer in order to block thiols on the peptides.
• Labeling the SNO group Up to 3 mM of reagent (with or without fluorophore) is incubated with the peptides or fixed cells for from about 30 mins to about 2 hours at room temperature. The excess reagent is separated by rinsing/HPLC separation or other methods such as dialysis. 4. Fluorosequencing: Fluorosequencing is performed on the fluorescently labeled peptides.
• This method can thus localize the residues of modification and quantify the stoichiometry of PTM labeling of the cysteine residue.
• Other variants of ligation of fluorophore with the intermediate phosphine adduct can be performed such as dehydroalanine formation as indicated in literature (Devari e-Baez el al, 2013).
• the common chemical derivatization strategy for nitrotyrosine, used in mass-spectrometry proteomics is a two-step process.
• the first step is the reduction of the nitro group to the amino group followed by covalently labeling the amino group with a specialized reagent.
• the other amino groups on the peptides/proteins are blocked, typically by acetylation (Abello et ctl, 2010; Devarie-Baez et ctl, 2013).
• This strategy (See Scheme 8) can be directly adapted for labeling the nitrotyrosine group with a distinct fluorophore for fluorosequencing.
• a method for labeling the nitrotyrosine for fluorosequencing application is described as follows: 1. Protein/peptide isolation: The isolated proteins and peptides are solubilized in sodium phosphate buffer (pH 7.5). The digested proteins or peptides can be lyophilized prior to analysis. The approximate concentration of the peptide is 10 mM.
• Acetylation of amines All the free amines and other nucleophiles are acetylated by incubating 190 pL of the nitrated peptide with NHS-Acetate (final concentration of 25 mM) for 2 h at room temperature. The //-acetylations were reversed and excess reagent hydrolyzed by boiling the reaction for 15 minutes.
• Citrullination is a post-translational modification caused by enzyme Protein Arginine deiminase (PAD) where the arginine side chain is converted to citrulline (process called deimination).
• PAD Protein Arginine deiminase
• the conversion leads to a change in the mass by lDa, the loss of the positive charge and two potential hydrogen bond donors.
• the modification has a major effect on protein structure and stability and is implicated in autoimmune disorders, neurodegenerative diseases and in tumor biology (Gy orgy et al, 2006).
• the small mass change overlaps with the isotopic distribution of unmodified Arginine residues in peptide mass-spectrometry, making its identification challenging.
• a chemoselective strategy for targeting citrullinated residue has been demonstrated.
• a phenylglyoxal reagent reacts with arginine (under basic) and citrulline (under acidic conditions) forming a five membered ring.
• the reagent additionally binds to homocitrulline and cysteine, the thiohemiacetal ring formed with cysteine is hydrolysed in neutral pH.
• Protein/peptide isolation The isolated proteins are digested or the peptide is isolated according to standard well optimized procedures. About 50 mM of citrullinated peptides is lyophilized or solubilized in 50 mM HEPES buffer (pH 7.5)
• citrulline containing peptide was incubated with 5 mM phenylglyoxal reagent and 20% Trichloroacetic acid (pH ⁇ l) for 3 hours at 37 °C.
• the phenylglyoxal reagent can be directly coupled with a fluorophore or contain a handle (click handle) for subsequent reaction with a fluorophore.
• Rhodamine-Phenylglyoxal reagent Selective labeling of citrullinated residue by Rhodamine-Phenylglyoxal reagent.
• A Reaction conditions for labeling of citrullinated residue.
• B Rhodamine - phenylglyoxal reagent used for fluorescently labeling citrullinated residues for fluorosequencing.
• Sulfenic acid is one of a specific oxidative modification of cysteine residue which is formed upon reaction of the thiol side chain with mild oxidizing environment.
• the modification is a readout of early stages of reactive oxygen species formation, the intermediate step for formation of disulfide bond formation and also involved in redox signaling (Poole et al, 2004).
• the unstable nature of the bond under commonly used ionization conditions in mass spectrometers makes localizing and quantifying the modification extremely challenging.
• the reactive nature of the group enables chemical coupling and enrichment of the modified peptides (Poole et al. , 2007; Reddie et al. , 2008) feasible.
• the principle is the selective reaction of the sulfenic acid with dimedone (5,5- dimethyl-l,3-cyclohexanedione) which has been linked to several fluorescent reagents (See Scheme 11). Additionally, a biotin labeled reagent may be used (Millipore; Cat # NS1226- 1MG).
• Protein/peptide isolation The proteins were digested or the peptides were isolated using common standardized procedures. About 1-10 pmol peptides were lyophibzed or solubilized in phosphate buffer (pH 7; 25 mM) and 1 mM EDTA. 2. Labeling of sulfenic acid: The fluorescent reagent was added to a concentration of 5 mM and incubated for 2 h at 37 °C. The reagent can be two halves - one with an azide handle and the second with a fluorophore that specifically reacts with the linker.
• troponin is a diagnostic biomarker for cardiac dysregulation (Wijnker et al, 2014).
• the site-specific nature of the phosphorylation is an important diagnostic and therapeutic marker for understanding and treating heart failures (Zhang et al. , 2012).
• the diagnosis may range from exercise to a disease state as severe as cardiac myopathy.
• the methods presented above can be easily adopted to assess the phosphorylation state of a number of potential phosphorylation related biomarkers.
• the first step would be to perform a standard antibody pulldown for the protein of interest, i.e. troponin.
• the enriched protein may be digested into shorter peptides using a protease, such as GluC or trypsin, producing peptides of a specific length.
• the phosphorylation sites can then be labelled on the peptide molecules as described in Example 1.
• This methodology may also be applied to assessing the methylation or glycosylation of any protein as well, providing new biomarkers for diseases which are characterized by post-translational modifications of the proteins.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Urology & Nephrology (AREA)
• Biomedical Technology (AREA)
• Hematology (AREA)
• Immunology (AREA)
• Chemical & Material Sciences (AREA)
• Physics & Mathematics (AREA)
• Food Science & Technology (AREA)
• Pathology (AREA)
• Cell Biology (AREA)
• Medicinal Chemistry (AREA)
• Biotechnology (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• General Physics & Mathematics (AREA)
• Microbiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Bioinformatics & Computational Biology (AREA)
• Biophysics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Peptides Or Proteins (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=69182408

Family Applications (1)

Country Status (5)

Cited By (10)

Families Citing this family (1)

Citations (5)

Family Cites Families (3)

• 2019
  • 2019-07-23 CN CN201980048949.XA patent/CN112469832A/zh active Pending
  • 2019-07-23 EP EP19840848.6A patent/EP3827093A4/en active Pending
  • 2019-07-23 WO PCT/US2019/042998 patent/WO2020023488A1/en not_active Ceased
  • 2019-07-23 JP JP2021503788A patent/JP2021530549A/ja active Pending
• 2021
  • 2021-01-22 US US17/155,298 patent/US20210215706A1/en active Pending

Patent Citations (5)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events